Serum endocan level in diabetes mellitus of patients with cirrhosis and risk of subsequent development of spontaneous bacterial peritonitis.

Serum endocan level in diabetes mellitus of patients with cirrhosis and risk of subsequent development of spontaneous bacterial peritonitis. J Physiol Pharmacol. 2019 Jun;70(3): Authors: Zuwala-Jagiello J, Pazgan-Simon M, Simon K, Kukla M, Murawska-Cialowicz E, Grzebyk E Abstract The presence of type 2 diabetes mellitus (DM) in patients with cirrhosis is associated with an increased risk of spontaneous bacterial peritonitis (SBP) which may represent an increased susceptibility to infections. Endocan is a key player in the regulation of inflammatory disorders, and a biomarker in bacteremia and sepsis. To investigate the association between both endocan and DM, and developing SBP, we conducted a retrospective cohort study. Three hundred and thirty patients (179 men, 151 women; mean age 61.0 ± 8.5 years) who were treated for liver cirrhosis were studied between January 2007 and December 2016. Univariate and multivariate analyses using age, type 2 diabetes mellitus, severity of cirrhosis (Child-Pugh or MELD score), platelet count, serum proinflammatory cytokines, procalcitonin, C-reactive protein, and endocan level were conducted to identify factors related to the development of SBP. Among 330 patients with the median follow-up of 6.0 years, the cumulative incidence of SBP at 5 years was 28.6%. On multivariate analysis, a high serum endocan level and DM were independent and significant risk factors for SBP development (hazard ratio (HR) 1.634 (95% CI: ...
Source: Journal of Physiology and Pharmacology - Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research

Related Links:

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: diabetes Out of Pocket Costs Voters for Cures Source Type: news
The latest crowdfunded research project undertaken by the SENS Research Foundation involves using the genetically engineered maximally modifiable mouse lineage in order to demonstrate the ability to copy a version of the ATP8 mitochondrial gene into the cell nucleus, a process known as allotopic expression, and thus prevent mutational damage to this gene from degrading mitochondrial function. This is a modest step on the road towards bringing this class of genetic engineering project to the point of readiness for commercial development, when a biotech startup company could be created to carry it forward. In just a f...
Source: Fight Aging! - Category: Research Authors: Tags: Activism, Advocacy and Education Source Type: blogs
The Food and Drug Administration approved AstraZeneca's drug Farxiga as a treatment for reducing the risk of hospitalizations for heart failure in adults with type-2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Farxiga, developed by AstraZeneca (NYSE: AZN) in a partnership with Bristol-Myers Squibb, already had FDA approval as a therapy along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug generated sales of more than…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Review in-depth clinical information, latest medical news, and guidelines on prevention and treatment of microvascular complications of diabetes, including diabetic nephropathy, diabetic neuropathy, and diabetic retinopathy.
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Resource Center Source Type: news
Publication date: Available online 21 October 2019Source: Molecular and Cellular EndocrinologyAuthor(s): Huiwen Ren, Ying Shao, Can Wu, Xiaoyu Ma, Chuan Lv, Qiuyue WangAbstractMetformin, as the basic pharmacological therapy and the first preventive drug in type 2 diabetes mellitus (T2DM), is proved to have potential protection in diabetic kidney disease (DKD). Here, we established a diabetic rat model induced by high-fat diet and low dose streptozotocin, and high glucose cultured rat mesangial cells (RMCs) pre-treated with metformin or transfected with AMPK, SIRT1 and FoxO1 small interfering RNA, and detected oxidative str...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
The Mickschl family in Minnesota creates hand-made Cure Mittens in crazy colors to raise awareness and money for type 1 diabetes.
Source: Diabetes Mine - Category: Endocrinology Authors: Source Type: blogs
ConclusionA considerable burden of previously unknown AF was detected when long-term monitoring was applied in at-risk patients. Biomarkers were associated with AF incidence and improved prediction of long AF episodes.
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 20 October 2019Source: American Heart JournalAuthor(s): Neha J. Pagidipati, Yinggan Zheng, Jennifer B. Green, Darren K. McGuire, Robert J. Mentz, Svati Shah, Pablo Aschner, Tuncay Delibasi, Helena W. Rodbard, Cynthia M. Westerhout, Rury R. Holman, Eric D. Peterson, on behalf of the TECOS Study GroupAbstractBackgroundObesity is a risk factor for type 2 diabetes (T2D) and cardiovascular disease (CVD). Whether obesity affects outcomes among those with T2D and atherosclerotic CVD (ASCVD) remains uncertain. Our objective was to investigate the relationship between body mass index (BMI) and ASC...
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 21 December 2018Source: Journal of Advanced ResearchAuthor(s): Undurti N. DasAbstractIt has been suggested that hepatitis B virus (HBV)- and hepatitis C virus (HCV)-induced hepatic damage and cirrhosis and associated hypoalbuminemia, non-alcoholic fatty liver disease (NAFLD), and alcoholic fatty liver disease (AFLD) are due to an imbalance between pro-inflammatory and anti-inflammatory bioactive lipids. Increased tumour necrosis factor (TNF)-α production induced by HBV and HCV leads to a polyunsaturated fatty acid (PUFA) deficiency and hypoalbuminemia. Albumin mobilizes PUFAs from t...
Source: Journal of Advanced Research - Category: Research Source Type: research
Publication date: Available online 21 December 2018Source: Journal of Advanced ResearchAuthor(s): Undurti N. DasAbstractIt has been suggested that hepatitis B virus (HBV)- and hepatitis C virus (HCV)-induced hepatic damage and cirrhosis and associated hypoalbuminemia, non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) are due to an imbalance between pro-inflammatory and anti-inflammatory bioactive lipids. Increased tumour necrosis factor (TNF)-α production induced by HBV and HCV leads to a polyunsaturated fatty acid (PUFA) deficiency and hypoalbuminemia. Albumin mobilizes PUFAs from th...
Source: Journal of Advanced Research - Category: Research Source Type: research
More News: Child Development | Children | Cirrhosis | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Liver | Peritonitis | Physiology | Study | Urology & Nephrology | Women